In a significant validation for India’s burgeoning deep-tech biotech sector, Cellogen Therapeutics has successfully closed a $2 million Pre-Series A funding round. The investment is a crucial injection of capital for a company tackling one of the most complex and expensive frontiers in modern medicine: cell and gene therapy. While software and fintech deals often dominate headlines, this financing represents a patient, high-conviction bet on fundamental science and India’s potential to become a hub for developing and manufacturing next-generation medical treatments.

The deal is more than just a financial milestone. It is a signal that Indian venture capital is maturing, moving beyond asset-light models to back companies with long research and development cycles but with the potential for transformative impact. For millions of patients in India suffering from rare genetic disorders and aggressive cancers, the promise of therapies developed by companies like Cellogen is not just innovation, it is hope for a cure that is both accessible and affordable.

The Mission to Engineer Cures in India

Founded in 2022 by a formidable duo, scientist Dr. Aruna Sharma and pharmaceutical operations expert Rohan Gupta, Cellogen Therapeutics was born from a shared vision. Dr. Sharma, who holds a PhD in Molecular Biology from the Indian Institute of Science (IISc), Bengaluru, spent years researching cell engineering techniques. She saw a glaring disconnect between the groundbreaking therapies being approved in the West and their near-total inaccessibility in India due to astronomical costs.

Cellogen Therapeutics is a research-first company dedicated to developing Chimeric Antigen Receptor T-cell (CAR-T) and other cell-based therapies. In simple terms, the company harvests a patient’s own immune cells (T-cells) and genetically engineers them in a lab to recognize and attack specific disease-causing agents, such as cancer cells or malfunctioning cells responsible for genetic disorders. These reprogrammed “living drugs” are then infused back into the patient.

Incubated at Bengaluru’s Centre for Cellular and Molecular Platforms (C-CAMP), the startup has focused its initial efforts on hematological malignancies (blood cancers) and specific monogenic disorders that have a higher prevalence in the South Asian population. Their early work, supported by government grants and a small seed investment, has already yielded a proprietary cell engineering platform that, according to the founders, can significantly streamline the manufacturing process, a key driver of the exorbitant costs associated with current-generation cell therapies.

Decoding the Pre-Series A Deal

The $2 million round was structured as a Pre-Series A, a financing instrument perfectly suited for a company transitioning from pure research to the crucial preclinical validation stage. The round was led by Endiya Partners, a venture capital firm known for its deep-tech and healthcare portfolio and its willingness to back product-focused startups with long gestation periods.

The investment thesis from Endiya Partners appears to be clear. They are not just investing in a single product but in a platform with the potential to generate a pipeline of therapies. The firm sees Cellogen’s approach to localizing R&D and manufacturing as a powerful strategy to disrupt the existing cost structure of cell therapies, which can run upwards of $400,000 per dose in the United States.

“We look for companies building foundational technologies with the potential for global impact,” a partner familiar with the firm’s thinking noted. “Cellogen’s team combines world-class scientific rigor with a pragmatic approach to manufacturing and cost-effectiveness. This is precisely what is needed to unlock the potential of cell therapy for a market like India.”

Joining Endiya Partners in the round was the healthcare-focused fund of Kotak Private Equity and a select syndicate of angel investors with deep domain expertise in the life sciences and pharmaceutical industries. The participation of strategic angels is particularly noteworthy, as their guidance on navigating India’s complex regulatory and clinical trial landscape will be as valuable as their capital.

While the company’s valuation was not disclosed, for a preclinical biotech firm, it would be based on the strength of its intellectual property, the novelty of its scientific platform, and the experience of its founding team, rather than on conventional revenue metrics.

Strategic Deployment of Capital

Cellogen has outlined a precise and milestone-driven plan for the deployment of this new capital. The funds are not for marketing or sales but are being funneled directly into the scientific and regulatory core of the business. The primary objectives for the next 18 to 24 months are clear.

  • Advancing Preclinical Research: A significant portion of the funds will be used to expand the scientific team and accelerate the preclinical studies for its lead therapeutic candidate. This involves rigorous testing in lab and animal models to establish safety and efficacy before seeking approval for human trials.
  • Strengthening the Technology Platform: The company will invest in further developing its proprietary cell engineering and manufacturing process. The goal is to create a more automated and scalable system that reduces both time and cost, a critical component of their affordability mission.
  • Securing Intellectual Property: Capital has been earmarked for filing a new set of international patents to protect their novel CAR-T constructs and manufacturing innovations, creating a defensive moat around their technology.
  • Navigating the Regulatory Pathway: Cellogen will use a part of the funding to engage with regulatory consultants and begin formal dialogues with India’s Central Drugs Standard Control Organisation (CDSCO) to chart a clear path toward securing approval for first-in-human clinical trials.

A Multi-Billion Dollar Opportunity with a Humanitarian Core

The global market for cell and gene therapy is exploding, projected to exceed $90 billion by the end of the decade. While the opportunity is immense, the barriers to entry are equally high, requiring deep scientific expertise, significant capital, and regulatory prowess. In India, the landscape is relatively nascent, with only a handful of startups like Immuneel Therapeutics (backed by Biocon and Dr. Kiran Mazumdar-Shaw) and Laurus Labs making headway.

Cellogen’s primary competitive advantage lies in its sharp focus on cost innovation from day one. While global pharmaceutical giants like Novartis and Gilead Sciences pioneered the first approved CAR-T therapies, their business models are predicated on high-price markets. Cellogen is building its entire scientific and operational stack with the Indian market in mind, aiming for a price point that could be an order of magnitude lower than Western alternatives.

This strategy positions them not as a direct competitor to Big Pharma in their home markets, but as a category creator in emerging economies where the need is vast and the existing solutions are unaffordable. Their success could create a blueprint for other Indian biotech firms to follow.

What Comes Next

With this fresh infusion of capital, Cellogen Therapeutics is now on the clock to deliver critical preclinical data. The company’s immediate goal is to complete the necessary studies to file an Investigational New Drug (IND) application with Indian regulators. This is the gateway to beginning Phase 1 clinical trials, the first time their therapy will be tested in human patients.

Rohan Gupta, co-founder and head of operations, emphasized that the Pre-Series A is a crucial bridge. “This capital allows us to de-risk our lead asset scientifically and prepare a robust data package for regulators,” he stated. “Our goal is to be ready for a larger Series A round within two years, which will be dedicated to funding our first clinical trial and scaling our manufacturing capabilities.”

For Dr. Sharma, the mission remains deeply personal. “These are not just diseases; they are devastating conditions that affect families across the country,” she shared. “Our work is driven by the belief that scientific breakthroughs should not be a luxury. With the support of our investors, we are one step closer to making these revolutionary cures a reality for patients in India.” The journey is long and fraught with scientific challenges, but for now, Cellogen has the fuel it needs to take the next critical step.